AdCOVID is a single dose intranasal vaccine candidate. AdCOVID in preclinical studies returned positive results.
AdCOVID showed strong serum neutralizing activity and potent mucosal immunity in the respiratory tract. The induction of mucosal IgA antibody in the respiratory tract may be necessary to block both infection and transmission of the virus to prevent further spread of COVID-19.
AdCOVID is indicated to prevent infection as well as transmission of COVID-19.
AdCOVID Clinical Trials
AdCOVID has completed preclinical studies that were conducted with the University of Alabama at Birmingham (UAB).
Based on the positive outcomes of the preclinical study, the Company plans to advance the vaccine candidate to a Phase 1 safety and immunogenicity study in Q4 of 2020.
March 30, 2020 - Altimmune, Inc. announced that it is launching a collaboration with the University of Alabama at Birmingham (UAB) on the development of its single-dose, intranasal COVID-19 vaccine, named AdCOVID